BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barbălată CI, Porfire AS, Sesarman A, Rauca VF, Banciu M, Muntean D, Știufiuc R, Moldovan A, Moldovan C, Tomuță I. A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy. Pharmaceutics 2021;13:1526. [PMID: 34683821 DOI: 10.3390/pharmaceutics13101526] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Duarte JA, Gomes ER, De Barros ALB, Leite EA. Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines. Pharmaceutics 2023;15:369. [DOI: 10.3390/pharmaceutics15020369] [Reference Citation Analysis]
2 Tefas LR, Toma I, Sesarman A, Banciu M, Jurj A, Berindan-neagoe I, Rus L, Stiufiuc R, Tomuta I. Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer. Journal of Liposome Research 2022. [DOI: 10.1080/08982104.2022.2153139] [Reference Citation Analysis]
3 Hashemi M, Ghadyani F, Hasani S, Olyaee Y, Raei B, Khodadadi M, Ziyarani MF, Basti FA, Tavakolpournegari A, Matinahmadi A, Salimimoghadam S, Aref AR, Taheriazam A, Entezari M, Ertas YN. Nanoliposomes for doxorubicin delivery: Reversing drug resistance, stimuli-responsive carriers and clinical translation. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.104112] [Reference Citation Analysis]
4 Bartkowiak A, Nazaruk E, Gajda E, Godlewska M, Gaweł D, Jabłonowska E, Bilewicz R. Simvastatin Coadministration Modulates the Electrostatically Driven Incorporation of Doxorubicin into Model Lipid and Cell Membranes. ACS Biomater Sci Eng 2022. [PMID: 36173110 DOI: 10.1021/acsbiomaterials.2c00724] [Reference Citation Analysis]
5 Bartos A, Iancu I, Ciobanu L, Onaciu A, Moldovan C, Moldovan A, Moldovan RC, Tigu AB, Stiufiuc GF, Toma V, Iancu C, Al Hajjar N, Stiufiuc RI. Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes—A Preliminary Study. Nanomaterials 2022;12:2833. [DOI: 10.3390/nano12162833] [Reference Citation Analysis]
6 Vlad R, Antonoaea P, Todoran N, Rédai E, Bîrsan M, Muntean D, Imre S, Hancu G, Farczádi L, Ciurba A. Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 23-Factorial Design. Pharmaceutics 2022;14:1467. [DOI: 10.3390/pharmaceutics14071467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ielciu I, Niculae M, Pall E, Barbălată C, Tomuţă I, Olah N, Burtescu RF, Benedec D, Oniga I, Hanganu D. Antiproliferative and Antimicrobial Effects of Rosmarinus officinalis L. Loaded Liposomes. Molecules 2022;27:3988. [DOI: 10.3390/molecules27133988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Foglizzo V, Marchiò S. Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy. Cancers (Basel) 2022;14:2473. [PMID: 35626078 DOI: 10.3390/cancers14102473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Negrea G, Rauca VF, Meszaros MS, Patras L, Luput L, Licarete E, Toma VA, Porfire A, Muntean D, Sesarman A, Banciu M. Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis. Front Pharmacol 2022;13:870347. [PMID: 35450036 DOI: 10.3389/fphar.2022.870347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rajput A, Butani S. Donepezil HCl Liposomes: Development, Characterization, Cytotoxicity, and Pharmacokinetic Study. AAPS PharmSciTech 2022;23:74. [PMID: 35149912 DOI: 10.1208/s12249-022-02209-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]